Skip to main content
Premium Trial:

Request an Annual Quote

Ipsum Diagnostics Coronavirus Test Gets FDA Emergency Use Authorization

NEW YORK — The US Food and Drug Administration on Wednesday granted Emergency Use Authorization to Ipsum Diagnostics for the company's RT-PCR-based SARS-CoV-2 test.

According to the FDA, the test, called COV-19 IDx, is designed to detect a region in the SARS-CoV-2 nucleocapsid gene, as well as human RNase P as a control, in nasopharyngeal and oropharyngeal swab specimens. Nucleic acid extraction is performed using Thermo Fisher Scientific's KingFisher Flex nucleic acid extraction system and the Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 kit, and the test runs on Thermo Fisher's Applied Biosystems QuantStudio 12 K Flex instrument.

Emergency use of the test is limited to Ipsum and other authorized laboratories, the FDA noted.

Atlanta-based Ipsum is offering COV-19 IDx supplies and kits via a physician portal on its website

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.